Article

AHAF launches 'See A Better Tomorrow' campaign

The American Health Assistance Foundation (AHAF) has launched “See A Better Tomorrow,” a public education campaign that encourages people to schedule comprehensive eye exams to help protect against irreversible vision loss caused by glaucoma or age-related macular degeneration (AMD).

Clarksburg, MD-The American Health Assistance Foundation (AHAF) has launched “See A Better Tomorrow,” a public education campaign that encourages people to schedule comprehensive eye exams to help protect against irreversible vision loss caused by glaucoma or age-related macular degeneration (AMD).

AHAF attests that early diagnosis is key to limiting or preventing vision loss from these two degenerative diseases, which affect 16 million Americans.

“Many people are unaware that they have these diseases until they start to experience symptoms, after irreversible vision loss may have occurred,” said AHAF president and chief executive officer Stacy Pagos Haller. “The good news is that with detection and treatment, eye doctors can often slow or stop the progression of these diseases and help protect against blindness.”

Through public service announcements and a wide range of resources, AHAF’s campaign asks people to visualize places or people they want to see, and then to protect their ability to continue seeing them by having an eye exam. For more information on the multi-platform campaign, visit www.ahaf.org/seeabettertomorrow.

AHAF is a nonprofit organization dedicated to finding cures for age-related degenerative diseases by funding research worldwide under its three program areas: Alzheimer’s disease research, macular degeneration research, and national glaucoma research (www.ahaf.org). To date, AHAF’s macular degeneration research and national glaucoma research programs have provided more than $31.5 million in grants to identify new prevention, diagnostic, and treatment options for people facing vision loss.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.